British urological surgery practice: 1. Prostate cancer

British Journal of Urology

Volumn 79, Issue 5, 1997, Pages 749-755

  Savage, P ^a   Bates, C ^a   Abel, P ^a   Waxman, J ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Management; Prostate cancer; Urological practice

Indexed keywords

GONADORELIN AGONIST;

ARTICLE; CONSULTATION; HUMAN; MALE; METASTASIS; PATIENT REFERRAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUESTIONNAIRE; UNITED KINGDOM;

EID: 0031398955     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1997.00238.x     Document Type: Article

References (32)

1. OPCS 1993. Mortality Statistics. HMSO 1995
2. Wingo PA, Tong T, Bolden S. Cancer statistics. 1995. CA Cancer J Clin 1995; 45: 8-30
3. Waxman J, Pandha H. Editorial: Do we know what's best for prostate cancer? Eur J Cancer 1996; 32: 1455-6
4. Kelly WK, Scher HI. Prostate cancer: how can a common disease be so controversial? Curr Opin Oncol 1994; 6: 318-31
5. TNM Classification of Malignant Tumours. Fourth Edition. Geneva: UICC. 1988
6. Savage P, Waxman J. PSA and prostate cancer diagnosis. Eur J Cancer 1996; 32A: 1097-9
7. Slawin KM, Ohori M, Dillioglugil O, Scardino PT. Screening for prostate cancer: an analysis of the early experience. CA Cancer J Clin 1995; 45: 134-47
8. Adolfsson J, Steineck G, Whitmore WF. Recent results of management of palpable clinically localised prostate cancer. Cancer 1993; 72: 310-22
9. Graversen PH, Nielsen KT, Gasser TC, Corle DK, Madsen PO. Radical prostatectomy versus expectant primary treatment in stages I and II prostatic cancer. A fifteen year follow-up. Urology 1990; 35: 493-8
10. Harlan L, Brawley O, Pommerenke F, Wali P, Kramer B. Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate. J Clin Oncol 1995; 13: 93-100
11. Van Aubel OG, Hoekstra WJ, Schroder FH. Early orchiectomy for patients with stage D1 prostatic carcinoma. J Urol 1985; 134: 292-4
12. Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group Studies. NCI Monograph 1988: 7: 165-70
13. Chodak GW, Thisted RA, Gerber GS et al. Results of conservative management of clinically localised prostate cancer. N Eng J Med 1994; 330: 242-8
14. Hanks GE, Diamond JJ, Krall JM, Martz KL, Kramer S. A ten year follow-up of 682 patients treated for prostate cancer with radiation therapy in the United States. Int J Radiation Oncol Biol Phys 1987; 13: 499-505
15. Zincke H, Bergstralh EJ, Blute ML et al. Radical prostatectomy for clinically localised prostate cancer: Longterm results of 1143 patients from single institution. J Clin Oncol 1994; 12: 2254-63
16. Catalona WJ, Basler JW. Return of erections and urinary continence following nerve sparing radical retropubic prostatectomy. J Urol 1993; 150: 905-7
17. Talcott JA, Riencer P, Propert K et al. Complications of treatment for early prostate cancer: A prospective, multiinstitutional outcomes study. Proc Am Assoc Clin Oncol 1994: 711
18. Ohori M, Goad JR, Wheeler TM, Eastham JA, Thompson TC, Scardino PT. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 1994; 152: 1843-9
19. Veterans Administration Cooperative Urological Research Group. Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967; 124: 1011-7
20. The MRC Prostate Cancer Working Party and Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. Br J Urol 1997; 79: 235-46
21. Kaisary AV, Tyrrell CJ, Peeling WB, Griffith K. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991; 67: 502-8
22. The Leuprolide Study Group. Leuprolide versus diethylstilboestrol for metastatic prostate cancer. N Engl J Med 1984; 311: 1281-6
23. Labrie F, Dupont A, Belanger A et al. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med 1982; 5: 267-75
24. Crawford ED, Eisenberger MA, McLeod DG et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Eng J Med 1989; 321: 419-24
25. Denis LJ, Carnelro de Moura JL, Bono A et al. Goserelin acetate and flutamide versus bilateral orchiectomy; a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology 1993; 42: 119-29
26. Prostate Cancer Triallists Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 1995; 346: 265-9
27. Denis LJ. Controversies in the management of localised and metastatic prostatic cancer. Eur J Cancer 1991; 27: 333-41
28. Horwich A, Waxman J, Schroder FH. Tumours of the prostate. Oxford Textbook of Oncology 1995: 1498-1530
29. Scher HI, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 1993; 11: 1566-72
30. Stone AR, Hargreave TB, Chisholm GD. The diagnosis of oestrogen escape and the role of secondary orchiectomy in prostatic cancer. Br J Ural 1980; 52: 535-8
31. Biorn GL, Gray CP, Strauss E. Orchiectomy after presumed oestrogen failure in the treatment of carcinoma of the prostate. Western J Med 1979; 130: 363-4
32. Hoskin PJ, Price P, Easton D et al. A prospective randomised trial of 4 Gy or 8 Gy single doses in the treatment of metastatic bone pain. Radiother Oncol 1992; 23: 74-8